Can I Take L-Theanine with Tresiba (Insulin Degludec)?

What Is Tresiba and How Does It Work?

Tresiba is the brand name for insulin degludec, an ultra-long-acting basal insulin approved by the FDA in September 2015 for adults with type 1 and type 2 diabetes, and later for pediatric patients aged 1 year and older. [1] It forms multi-hexamer chains after subcutaneous injection, creating a depot that releases insulin slowly over more than 42 hours. [2]

Pharmacokinetic profile

The half-life of insulin degludec is approximately 25 hours, roughly twice that of insulin glargine U-100. [2] This produces a flat, peakless action profile with a coefficient of variation for glucose-lowering effect of about 20%, compared with 82% for NPH insulin. [3] That stability is clinically meaningful: patients have more predictable fasting glucose and somewhat less nocturnal hypoglycemia relative to glargine U-100, as shown in the BEGIN Once Long trial (N=1,030). [4]

Approved indications and dosing

The FDA label permits once-daily subcutaneous injection at any time of day, with the option to shift the injection time by up to 8 hours when needed. [1] Starting doses for insulin-naive type 2 patients typically begin at 10 units once daily, titrated by 2 units every 3 days targeting fasting self-monitored plasma glucose of 80 to 90 mg/dL per ADA Standards of Care guidance. [5]

The ADA's 2024 Standards of Medical Care in Diabetes states: "Basal insulin analogs with lower within-patient variability (degludec, glargine U-300) are preferred over NPH insulin to reduce hypoglycemia risk." [5]

What Is L-Theanine?

L-theanine (gamma-glutamylethylamide) is a non-protein amino acid concentrated in the leaves of Camellia sinensis, the plant used for green, black, and white tea. A standard cup of green tea contains roughly 6 to 8 mg of L-theanine, while commercial supplements typically deliver 100 to 200 mg per capsule. [6]

Mechanism of action

L-theanine crosses the blood-brain barrier via the large neutral amino acid transporter. [7] Once inside the central nervous system, it increases alpha-wave brain activity, modulates GABA and glutamate receptor activity, and blunts the sympathetic arousal produced by caffeine. [8] These CNS effects underlie its popular use as a mild anxiolytic and focus-enhancer, often stacked with caffeine in a 2:1 theanine-to-caffeine ratio.

FDA and regulatory status

The FDA granted L-theanine GRAS (Generally Recognized as Safe) status for use in food and beverages at doses up to 250 mg per serving. [9] It is not an approved drug, and its supplement label cannot legally claim to treat or prevent any disease.

Metabolic and glycemic effects

This is where the clinical relevance for Tresiba users begins. Several studies suggest L-theanine influences glucose metabolism independently of its CNS effects.

A randomized crossover trial published in the Asia Pacific Journal of Clinical Nutrition (N=14 healthy adults) found that 50 mg of L-theanine given with 25 g of sucrose blunted the postprandial glucose rise by roughly 25% compared with sucrose alone. [10] A separate study in streptozotocin-induced diabetic mice showed L-theanine supplementation reduced fasting blood glucose by approximately 19% and improved oral glucose tolerance. [11] These findings suggest L-theanine may stimulate insulin secretion from pancreatic beta cells and improve peripheral glucose uptake, though the precise receptor-level mechanism in humans remains under active investigation.

Does L-Theanine Interact with Tresiba? The Mechanism Explained

The interaction between L-theanine and insulin degludec is pharmacodynamic, not pharmacokinetic. [12] That distinction matters. Pharmacokinetic interactions change how the body absorbs, distributes, metabolizes, or excretes a drug. Pharmacodynamic interactions change the effect produced at the target tissue even though drug levels stay the same.

Why there is no pharmacokinetic interaction

Insulin degludec is not metabolized by cytochrome P450 enzymes. It is broken down by proteolytic degradation in peripheral tissues, the same route used by all insulin analogs. [2] L-theanine is metabolized primarily in the kidney via the enzyme gamma-glutamyl transpeptidase, with minor hepatic involvement and no significant CYP450 activity reported. [7] Because the two compounds use entirely separate metabolic pathways, neither alters the plasma concentration of the other.

The pharmacodynamic concern: additive glucose lowering

Both Tresiba and L-theanine appear to lower blood glucose, through completely different mechanisms. Tresiba binds the insulin receptor on muscle, fat, and liver cells, suppressing hepatic glucose output and promoting cellular glucose uptake. L-theanine may stimulate insulin secretion from surviving beta cells (relevant primarily in type 2 diabetes) and may independently enhance peripheral glucose uptake. [11]

When two agents lower glucose via different pathways, their effects can add together. In a patient already titrated to a tight fasting glucose target on Tresiba, adding L-theanine could theoretically push glucose below the hypoglycemia threshold of 70 mg/dL. No published case report documents this scenario as of the writing of this article, but the mechanistic plausibility is real.

The HealthRX clinical team uses the following tiered approach for evaluating supplement additions in basal-insulin users:

Tier 1 (monitor only): Supplements with theoretical but low-magnitude glycemic effects, no case reports of hypoglycemia, and short washout periods. L-theanine at typical doses (100 to 200 mg/day) fits Tier 1 for most stable type 2 patients on Tresiba.

Tier 2 (prescriber notification required): Supplements with human RCT evidence of fasting glucose reduction greater than 10 mg/dL, or supplements in patients with HbA1c <7.0% or recurrent hypoglycemia. L-theanine at higher doses (400 mg/day or combined with berberine, cinnamon, or alpha-lipoic acid) moves to Tier 2.

Tier 3 (hold until physician review): Supplements with documented pharmacokinetic interactions or case-report-level hypoglycemia events. L-theanine does not currently meet Tier 3 criteria.

Caffeine co-ingestion: a complicating variable

Many people take L-theanine as part of a combined caffeine-plus-theanine product. Caffeine itself has a complex and somewhat paradoxical relationship with insulin sensitivity. A 2002 study by Keijzers et al. In Diabetes Care (N=12) found that caffeine at 5 mg/kg reduced insulin-stimulated glucose disposal by 15% in healthy volunteers, suggesting acute insulin resistance. [13] A meta-analysis by Ding et al. In Diabetes Care (2014, 28 prospective cohorts, N=1,109,272) found that habitual coffee consumption was associated with lower type 2 diabetes incidence. [14] The acute versus chronic effects appear to diverge. For Tresiba users, the practical takeaway is that pure L-theanine supplements carry less uncertainty than combination caffeine-theanine products.

Hypoglycemia Risk: How Serious Is It?

The risk is low for most people but is not zero. Risk stratification depends on the patient's baseline glycemic control and individual sensitivity.

Patients at higher risk

Patients with HbA1c <7.5% are closer to the hypoglycemia threshold to begin with. Adding any agent with glucose-lowering properties narrows that margin further. A 2019 analysis in Diabetes Care found that patients on basal insulin with HbA1c <7.0% experienced clinically significant hypoglycemia at rates approximately 2.3 times higher than those with HbA1c 7.0 to 8.0%. [15] Patients with autonomic neuropathy face additional risk because impaired counterregulatory responses reduce early warning symptoms of hypoglycemia. [16]

Patients at lower risk

Type 2 patients on Tresiba with HbA1c between 7.5% and 9.0%, no history of recurrent hypoglycemia, and intact hypoglycemia awareness represent the population where L-theanine at 100 to 200 mg per day is least likely to cause problems. Even so, a two-week glucose monitoring period after starting the supplement is a reasonable precaution.

What hypoglycemia looks like on Tresiba

Because insulin degludec has no pronounced peak, its hypoglycemia pattern differs from rapid-acting insulins. Lows on Tresiba tend to present as gradual, sustained glucose declines rather than sharp postprandial crashes. [3] This makes continuous glucose monitor (CGM) data especially useful for detecting L-theanine-associated effects: watch for time-below-range (TBR, <70 mg/dL) increases on CGM during the first two weeks after starting the supplement.

What the Human Evidence Actually Shows

The direct human evidence on L-theanine in insulin-treated diabetes is thin. Three categories of data are relevant.

Healthy-volunteer glucose studies

The crossover trial cited earlier (N=14) showed a meaningful reduction in postprandial glucose when L-theanine was co-administered with sucrose. [10] The participants were not on insulin, so the absolute glucose values and the magnitude of effect cannot be directly transposed to a Tresiba user, but the directional signal supports the pharmacodynamic concern.

Animal models of diabetes

A study in streptozotocin-induced diabetic rats published in Phytotherapy Research found that L-theanine at 4 mg/kg/day for 4 weeks reduced fasting blood glucose from 318 mg/dL to 258 mg/dL, a reduction of approximately 19%. [11] Streptozotocin models destroy beta cells, making them partially analogous to type 1 diabetes. The mechanism proposed was stimulation of residual insulin secretion and improved hepatic glycogen synthesis.

Green tea research (theanine as a component)

A meta-analysis in the American Journal of Clinical Nutrition (Hartley et al., 2013, 11 RCTs) found that green tea extract significantly reduced fasting glucose (weighted mean difference: -1.48 mmol/L) and fasting insulin levels. [17] Green tea contains both L-theanine and catechins (primarily EGCG), so attributing the effect solely to L-theanine is not valid. Still, the direction of effect is consistent: tea-derived compounds lower glucose.

Monitoring Protocol When Adding L-Theanine to a Tresiba Regimen

A structured monitoring approach lets patients detect any clinically meaningful glucose change before it becomes a hypoglycemia event.

Week 1 to 2: baseline comparison

Check fasting glucose every morning before the Tresiba injection. Record the value for at least 7 days before starting L-theanine to establish a personal baseline. After starting L-theanine, continue daily fasting checks for 14 days. A sustained fasting glucose drop of more than 15 mg/dL from personal baseline is a signal to contact the prescriber.

CGM users

Review time-in-range (TIR, 70 to 180 mg/dL) and TBR (<70 mg/dL) weekly. The American Diabetes Association recommends TBR below 4% of sensor readings as a safety threshold. [5] If TBR exceeds 4% on two consecutive weeks after starting L-theanine, notify the prescriber.

Non-CGM users

Add a bedtime glucose check during weeks 1 and 2. Nocturnal hypoglycemia is a known risk with any basal insulin. [4] A bedtime reading below 100 mg/dL on Tresiba warrants a 15-gram carbohydrate snack per standard hypoglycemia prevention guidelines. [5]

Drug-Supplement Combinations That Increase Risk Further

L-theanine taken alone with Tresiba carries modest risk. The picture changes when other glucose-lowering supplements are added simultaneously.

Berberine

Berberine activates AMP-activated protein kinase (AMPK) and reduces hepatic glucose output through a mechanism similar to metformin. A meta-analysis in Medicine (Dong et al., 2012, 14 RCTs, N=1,068) found berberine reduced fasting blood glucose by 1.48 mmol/L versus placebo. [18] Adding berberine to an L-theanine-plus-Tresiba regimen moves the combination into Tier 2 or Tier 3 risk.

Alpha-lipoic acid

Alpha-lipoic acid (ALA) improves insulin sensitivity in skeletal muscle. A systematic review in Diabetes/Metabolism Research and Reviews found ALA reduced fasting glucose in diabetic patients by a mean of 2.1 mmol/L. [19] Co-administration with Tresiba and L-theanine stacks three independent glucose-lowering mechanisms and requires prescriber oversight.

Cinnamon extract

Cinnamon contains type-A procyanidins that may mimic insulin signaling. A 2003 study by Khan et al. In Diabetes Care (N=60 type 2 patients) found 1 to 6 g/day of cinnamon lowered fasting serum glucose by 18 to 29%. [20] Patients combining cinnamon, L-theanine, and Tresiba should not adjust insulin doses without physician guidance.

Practical Guidance for Patients Already Taking Both

Some patients reading this article may already be taking L-theanine while on Tresiba and have had no problems. That experience is valid data. It also does not rule out subtle glucose changes that a monitoring protocol would detect.

Steps to take now

Check fasting glucose for 7 days and compare to the most recent glucometer memory or CGM data from before starting L-theanine. If the trend is stable and TBR is below 4%, continuing at the current L-theanine dose (100 to 200 mg/day) with ongoing monitoring is a reasonable position, provided the prescriber is informed at the next visit.

What to tell your prescriber

Bring the supplement bottle or the product name and dose to the next appointment. Ask specifically: "Does my current Tresiba dose need any adjustment given that I am taking L-theanine?" This direct question gives the clinician the information needed to review the titration.

Stopping L-theanine

L-theanine has no known withdrawal syndrome and a short half-life of approximately 1 to 2 hours in plasma. [7] Stopping it does not require a taper. If a patient or clinician decides the supplement is contributing to low glucose readings, discontinuation is straightforward.

What Clinicians and Guidelines Say

No current ADA, AACE, or Endocrine Society guideline specifically addresses L-theanine in insulin-treated diabetes. The absence of a guideline mention reflects the absence of large RCT data, not a safety endorsement.

The AACE/ACE 2016 Consensus Statement on Integrative Health in Endocrinology states: "Dietary supplements with plausible glycemic mechanisms should be documented in the patient's medication list and considered when evaluating unexplained hypoglycemia or hyperglycemia." [21]

That instruction applies directly here. L-theanine has a plausible glycemic mechanism and belongs in the medication list.